Navigation Links
Vasogen's Research Published in European Journal of Neuroscience
Date:1/28/2008

continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relat
'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Researchers Pinpoint Best Treatment to Reduce Deadly USA300, MRSA Staph Infections
2. Researchers develop darkest manmade material
3. Clinimetrics Celebrates 20th Anniversary in Contract Research Business
4. Quintiles to Open Clinical Research Office in Wilmington, NC
5. Irving Dark Named Vice President of Cytel Clinical Research Services
6. Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers
7. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
8. Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally
9. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
10. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
11. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... The Medical Innovation Impact Index (MI3), a new ... innovation, has been developed at the Initiative for ... ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ... FDA (Food & Drug Administration) draft guidance documents and ... medical devices. , “The main impediment to innovation ...
(Date:5/26/2015)... Regenestem Network has announced the grand opening ... Argentina. The clinic will be lead by Silvina Pastrana, ... a multidisciplinary team of medical professionals who specialize in ... office. , The new Regenestem Network members plan ... in cellular therapies, and establish Regenestem protocols to isolate ...
(Date:5/26/2015)... Kalifornien und HILDEN, Deutschland, May 26, 2015 ... Insight ®   ermöglicht ... die Erstellung dazugehöriger Berichte; Vorstellung auf den ... QIAGEN N.V. (NASDAQ: QGEN ; ... Markteinführung von QIAGEN Clinical Insight ® ...
(Date:5/26/2015)... 2015   Intrexon Corporation (NYSE: XON ), ... Frost , Ph.D., Senior Vice President and Head of Intrexon,s ... Conference on Wednesday, June 3 rd , at 1:30 p.m. ... York City . About Intrexon Corporation ... Bioindustrial Revolution with Better DNA ™ to create biologically-based ...
Breaking Biology Technology:Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2
... continue to have access to ZEVALIN(R) and other novel ... ... New Medicare legislation,passed by the House and Senate extends the ... and Medicaid,Services (CMS) had implemented new hospital outpatient reimbursement rates,for ...
... (Nasdaq: ALXA ) announced today that it has ... Directors. Dr. Barron is currently,Senior Vice President, Development and ... organization, which is responsible for,pre-clinical, clinical and post-approval activities., ... clinical scientist and was,promoted in 2002 to Vice President ...
... Amicus Therapeutics,Inc. (Nasdaq: FOLD ), ... chaperones for the treatment of human,genetic diseases, ... Phase 2 clinical trials of Amigal(TM) (migalastat ... Amigal is being developed in,partnership with Shire ...
Cached Biology Technology:House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 2House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 3Alexza Elects Dr. Hal V. Barron to Its Board of Directors 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 3Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 2Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 3Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 4Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 5Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 6
(Date:4/27/2015)... -- For more than four decades, AUVSI,s Unmanned Systems ... worldwide event for the unmanned land, sea, and air ... any local, national, or trade news organization interested in ... current applications of unmanned technologies. The conference will explore ... industry, and how it will soon impact the lives ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Tampa, Fla. (Mar. 12, 2009) A study to ... from a combination of autologous (patient self-donated) stem cell ... of ) oxygen treatment (HBO) before and after ASC ... glycemic control" along with "reduced insulin requirements." The combination ...
... a profound role in regulating global climate. But the ... have long struggled to accurately measure their composition, size, ... new satellite instrument developed by NASA scientists, the Aerosol ... Some types of small aerosols -- such as black ...
... software developed with help from the Wildlife Conservation Society ... by creating a three-dimensional model using photos taken by ... of the journal Biology Letters , may also ... The new software, developed by Conservation Research Ltd., creates ...
Cached Biology News:Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes 2New aerosol observing technique turns gray skies to blue 2New aerosol observing technique turns gray skies to blue 3New aerosol observing technique turns gray skies to blue 4Tracking tigers in 3-D 2
... is an optical unit that can be ... Dyad Disciple gradient-capable thermal cycler (purchased separately). ... shuttle that contains four LEDs for fluorescence ... 620-650 nm) and two filtered photodiodes for ...
... (LCM) is the method of choice for ... the only instrument to offer both LCM ... UV Laser Cutting provides unprecedented ... and capturing large numbers of cells. , ...
... highly sensitive laser confocal systems designed for ... scanners that meet your expectations, differentiating between ... optimizing the signal on the bottom as ... range for increased sensitivity. Results with VersArray ...
Hybridizer (220 V) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
Biology Products: